相关临床试验
87
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1876
进行中（未招募）
1
1.1%
已完成
55
63.2%
Enrolling By Invitation
1
1.1%
尚未招募
3
3.5%
招募中
18
20.7%
终止
1
1.1%
Unknown
6
6.9%
撤回
2
2.3%
暂无批准数据
- Researchers at CU Anschutz and CU Boulder developed Opto2P-FCM, a 5-gram head-mounted miniature microscope that simultaneously images and optogenetically stimulates individual neurons during natural movement. - The dual-path optical design separates high-resolution imaging from targeted light-based stimulation, allowing each function to be optimized independently for clearer images and more precise control. - The technology could accelerate research into neurological diseases such as Alzheimer's disease, Parkinson's disease, and epilepsy by revealing how healthy brain circuits function and how disease disrupts them. - The current device is a prototype, with future versions planned to be smaller, lighter, faster, and to offer a larger field of view.
- Renovare Therapeutics launched from stealth mode in April 2026, collaborating with University of Colorado Boulder on a $33.5 million ARPA-H contract to develop regenerative osteoarthritis therapies. - The company's platform technologies include controlled drug delivery systems, novel gene therapies, and advanced regenerative biomaterials designed to halt and reverse osteoarthritis disease progression. - Lead product candidates are advancing toward IND-enabling studies in 2026, targeting the more than 32 million Americans affected by osteoarthritis with potentially transformative regenerative treatments. - The leadership team includes industry veterans with experience guiding nine products through clinical development and regulatory approvals, culminating in over $18 billion in acquisitions.
- University of Colorado Boulder researchers discovered that para-tyramine-O-sulfate (pTOS), a metabolite found in python blood, acts as an appetite suppressant in mice without causing gastrointestinal problems or muscle loss. - The compound increases 1,000-fold in pythons after feeding and targets the brain's hunger center, leading to weight loss in both obese and lean mice when administered at high doses. - Scientists have formed Arkana Therapeutics to develop synthetic versions of pTOS and other python metabolites into commercial weight loss drugs that could avoid common side effects of current GLP-1 medications. - The research represents a nature-inspired approach to drug development, leveraging pythons' extraordinary ability to survive extreme feeding cycles without metabolic damage.
- Ascidian Therapeutics has assembled a distinguished Scientific Advisory Board featuring globally recognized RNA biology experts to guide its RNA exon editing platform development. - The company appointed Dr. Murray Abramson as Chief Development Officer, bringing over 25 years of clinical development experience including successful filings of more than 6 NDAs and BLAs. - ACDN-01, the first RNA exon editor in clinical development, is currently being evaluated in the Phase 1/2 STELLAR trial for Stargardt disease, representing the most advanced clinical program targeting the underlying cause of this inherited retinal disorder. - The company's RNA exon editing technology enables precise, kilobase-scale editing of RNA in vivo without foreign enzymes or genomic alterations, potentially addressing diseases that have eluded conventional gene therapies.
